1.	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy Phase: Phase IV Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446GUS45, ZENITH, NCT00063609
2.	A Multiple Myeloma Trial in Patients With Bone Metastases Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446EUS97, US97, NCT00104104
3.	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases Phase: Phase IV Type: Supportive care Status: Completed Age: 18 to 120 Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446EIT04, NCT00219219
4.	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer Phase: Phase IV Type: Treatment Status: Closed Age: 18 to 80 Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446GGR01, NCT00219271
5.	Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446EDE06, NCT00171964
6.	Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446EDE15, NCT00172003
7.	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer Phase: Phase IV Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446EDE28, NCT00334139
8.	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer Phase: Phase IV Type: Diagnostic, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446GDE22, NCT00391690
9.	Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Phase: Phase IV Type: Natural history/Epidemiology, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446EAU22, NCT00434447
10.	Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients Phase: Phase IV Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446EUS129, NCT00622505
11.	Stage I Multiple Myeloma Treatment Phase: Phase IV Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: IFM-04-01, NCT00733538
12.	Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Phase: Phase IV Type: Treatment Status: Closed Age: Over 18 Sponsor: Other Protocol IDs: CZOL446ECN06T, NCT00762346
13.	Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates Phase: Phase IV Type: Treatment Status: Closed Age: Over 18 Sponsor: Other Protocol IDs: CZOL446ECN07, NCT00765687
14.	Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients Phase: Phase IV Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446EUS147, NCT01129336
15.	Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer Phase: Phase III, Phase II Type: Treatment Status: Closed Age: Postmenopausal Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446GDE19, NCT00375752
16.	Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 to 75 Sponsor: Other Protocol IDs: CZOL446ECN05, NCT00524849
17.	Phase III Randomized Study of Zoledronate for the Prevention of Bone Loss in Premenopausal Women Receiving Adjuvant Chemotherapy For Early Stage Breast Cancer Phase: Phase III Type: Supportive care Status: Closed Age: 18 to 50 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: CPMC-IRB-14069, NCI-G02-2127, NOVARTIS-CPMC-IRB-14069, NCT00049452
18.	Phase III Randomized Study of Neoadjuvant or Adjuvant Chemotherapy and/or Hormonal Therapy With Versus Without Zoledronate in Women With Stage II or III Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: SHEFF-AZURE, EU-20315, ISRCTN79831382, BIG-1-04, NCT00072020
19.	Phase III Randomized Study of Zoledronate for the Prevention of Skeletal-Related Events in Patients With Prostate Cancer and Bone Metastases Undergoing Androgen Deprivation Therapy Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-90202, ECOG-CALGB-90202, NCT00079001, SWOG-CALGB-90202, CAN-NCIC-PRC2
20.	Phase III Randomized Study of Immediate Versus Delayed Zoledronate for Prevention of Bone Loss in Postmenopausal Women With Stage I-IIIA Breast Cancer Initiating Letrozole After Prior Treatment With Tamoxifen Phase: Phase III Type: Supportive care, Treatment Status: Closed Age: Postmenopausal Sponsor: NCI Protocol IDs: NCCTG-N03CC, NCT00107263, N03CC, NCCTG N03CC
21.	Phase III Randomized Study of Adjuvant Zoledronate Versus Clodronate Versus Ibandronate in Women With Resected Primary Stage I-III Adenocarcinoma of the Breast Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0307, NCCTG-SWOG-S0307, ECOG-SWOG-S0307, NSABP-SWOG-S0307, CALGB-SWOG-S0307, CAN-NCIC-SWOG-S0307, S0307, NCT00127205
22.	Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD) Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: MCC-13043, CZOL446E, NCT00215943
23.	Effects of Zometa and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer Phase: Phase III Type: Supportive care Status: Completed Age: 40 to 55 Sponsor: Other Protocol IDs: 1769-03-A, CZOL446E, NCT00202059
24.	The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446EUS72, NCT00171639
25.	A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC) Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446G2419, NCT00172042